- We will send in 10–14 business days.
/images/books/12350873/9781839694158.jpg)
- Author: Erlinda M Gordon
- Publisher: IntechOpen
- ISBN-10: 1839694157
- ISBN-13: 9781839694158
- Format: 17 x 24.4 x 0.6 cm, hardcover
- Language: English
- SAVE -10% with code: EXTRA
Reviews
Description
The revival of DeltaRex-G (formerly Rexin-G)-the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history-returned active tumor surveillance and a precision-guided "silver bullet" (dnG1 killer gene) to the cancer clinic with "Expanded Access" in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of "informed consent," this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors-validating "pathotropic" (disease-seeking) tumor targeting avant la lettre.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 16d.21:24:02
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Erlinda M Gordon
- Publisher: IntechOpen
- ISBN-10: 1839694157
- ISBN-13: 9781839694158
- Format: 17 x 24.4 x 0.6 cm, hardcover
- Language: English English
The revival of DeltaRex-G (formerly Rexin-G)-the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history-returned active tumor surveillance and a precision-guided "silver bullet" (dnG1 killer gene) to the cancer clinic with "Expanded Access" in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of "informed consent," this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors-validating "pathotropic" (disease-seeking) tumor targeting avant la lettre.
Reviews